IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase

Table 3 Hepatitis C virus genotype 1-infected patient with persistent normal alanine aminotransferase and interleukin 28B single-nucleotide polymorphism

IL-28B rs8099917	Major	Minor	P value	SVR	Non-SVR	P value
Number of patients	54	18		36	36
Age (yr)	58.4 ± 10.9	54.6 ± 11.0	0.20	56.6 ± 13.4	58.4 ± 8.0	0.49
Gender (male/female)	17/37	7/11	0.77	14/22	10/26	0.45
AST (IU/L)	30.3 ± 14.5	34.5 ± 10.3	0.29	13.2 ± 1.1	32.0 ± 6.3	< 0.00010
ALT (IU/L)	27.5 ± 6.7	31.7 ± 5.6	0.019	27.3 ± 7.4	29.8 ± 5.7	0.11
γ-GT (IU/L)	21.7 ± 11.9	47.3 ± 39.3	0.00024	19.7 ± 10.6	39.2 ± 32.7	0.0011
WBC (/mm3)	5020 ± 1410	4570 ± 1350	0.27	5000 ± 1350	4780 ± 1470	0.51
Hemoglobin (g/dL)	13.3 ± 0.9	13.7 ± 1.5	0.17	13.2 ± 1.1	13.5 ± 1.1	0.25
Platelets (× 104/mm3)	16.6 ± 6.0	17.0 ± 5.6	0.80	17.1 ± 6.0	16.2 ± 5.8	0.51
Previous Treatment (-/+)	42/12	12/6	0.52	29/7	25/11	0.41
VR/Null response	46/8	9/9	0.0064	36/0	19/17	< 0.00010
RVR (+/-)	6/38	0/16	0.28	6/27	0/27	0.057
EVR (+/-)	25/19	1/15	0.0013	23/10	3/24	< 0.00010
SVR (+/-)	34/20	2/16	0.00040
IL-28B SNP rs8099917
(Maj/Min)				34/2	20/16	0.00040

Data are expressed as the mean ± SD. P values are for comparisons between the major genotype group and minor genotype group or between sustained virologic response (SVR) and non-SVR groups by Student’s t-test or the χ² test. AST: Aspartate aminotransferase; γ-GT: Gamma-glutamyl transpeptidase; WBC: White blood cell count; IL-28B: Interleukin 28B; Maj: Major genotype; Min: Minor genotype; VR: Virologic response; RVR: Rapid virologic response; EVR: Early virologic response; SVR: Sustained virologic response.